Online reporter conference plan revealed
“It is important to secure domestic vaccine sovereignty”
viewer
Celltrion (068270)The new coronavirus infection (Corona 19) treatment’Rekironaju’ is planning to finish the phase 3 clinical administration within 3 months. It has begun to develop additional therapeutic agents to respond to the mutant virus, and is also considering developing a vaccine.
Celltrion Honorary Chairman Seo Jeong-jin held an online press conference on the 18th and announced this plan. Regarding the status of Phase 3 of Rekirona, Chairman Seo said, “It has been 1 month since (clinical) started, but 150 people have received the treatment as of yesterday.” I see it as” he explained.
Earlier, Celltrion succeeded in developing the first domestic corona antibody treatment, Rekironaju (ingredient name Regdanvimab CT-P59). Therapies have been supplied to medical institutions since the 17th, and the subjects to be administered are patients with corona19 confirmed and who do not require oxygen therapy within 7 days from the date of onset of symptoms, who are over 60 years of age, patients with underlying diseases, or patients with pneumonia.
viewer
On this day, Chairman Seo said that he is also considering developing a vaccine. Chairman Seo said, “We already have a system for diagnosis such as a diagnostic kit, and we have secured technological sovereignty for COVID-19 treatment with the approval of antibody treatment. However, in the case of vaccines, it is dependent on overseas introduction, so whether domestic vaccines can follow? Homework” he said.
He said, “To put out a wildfire, we shouldn’t follow the fire, but we have to go ahead and build a firewall.” I was concerned.
It is understood that the world is known to have initiated the development of a vaccine for the COVID-19 mutation, and it is interpreted that if Korea lags behind in the development of the vaccine, it will jump into the development.
Honorary Chairman Seo said, “We are ready to make a vaccine,” he said. “It is not what the Corona 19 vaccine wants to do, but it means that if the supply to Korea is delayed when we need to make bivalent and trivalent vaccines according to future variations.” Explained.
He added, “It is not a business with economic feasibility, but if it is necessary for national technological independence, we are ready to do it urgently without considering profitability,” he added. “First, I hope to secure vaccine sovereignty.”
Cocktail treatments that can respond to mutant viruses are also being developed. Chairman Seo said, “We have built a pool of neutralizing antibodies that will confidently respond to any mutations,” and said, “We will end phase 2 clinical trials within six months after developing a mutant-response cocktail treatment using candidate antibody No. 32.”
The clinical trial is conducted as a single clinical trial in South Africa. It is expected to enter animal testing next month. Previously, as a result of the test for the ability to neutralize the foreign mutant virus of Rekkirona, the British mutant showed strong neutralizing ability, but the neutralizing ability of the South African mutant virus was decreased. However, Antibody No. 32 possessed by Celltrion showed neutralizing ability in both British and South African mutants. In the cocktail therapy test combined with Rekirona, he confirmed its neutralizing ability and started developing a cocktail treatment.
Chairman Seo said, “The development of the antibody treatment was to secure the sovereignty of the treatment, not for profit.” “I think it is an irresponsible remark about some experts’ point that Rekirona can be a poison rather than a drug. I’m fine, but I hope you don’t make even the employees feel unworthy.”
/ Reporter Joo-won Lee [email protected]
< 저작권자 ⓒ 서울경제, 무단 전재 및 재배포 금지 >